“I’m still enthusiastic. Just a bit less naïve.” Salva Guardiola, PhD student in Ernest Giralt’s Design, Synthesis, and Structure of Peptide and Proteins Lab, has just published his first paper in ChemBioChem. And in the life of a researcher, the first article is never forgotten, it leaves a mark the rest of your career.
The idea Salva and his colleagues had was to design and test a peptide,...
The medical portal ""El Médico Hospitaliario" and other media report on IRB Barcelona's research on compounds able to act against EGF, a little-explored cancer target.
The study has been published in ChemBioChem.
The molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target.
The long-term goal is to provide a new chemotherapy treatment.
After seven intense years in Ernest Giralt’s lab, Laura Nevola (Benevento, Italy, 1980) is ready to undertake a new challenge in her career. “It’s time to fly on my own,” she says.
This award recognizes his thesis, which addressed the use of shuttle peptides to overcome the blood-brain barrier.
La Vanguardia, Diario Médico and many other media, up to 100, have reported on the Blood-Brain Barrier congress held in Barcelona and organised by IRB Barcelona and the BBVA Foundation.
It has been known for 100 years that the brain is protected by thousands of tight capillaries that form a barrier—a defence mechanism but also an obstacle to the use of promising drugs to treat diseases affecting the central nervous system.
Ernest Giralt: “This barrier is responsible for the low success rate of new drugs to enter the brain. We now have the strategies to overcome it.”
20 pioneering scientists present their latest research on the barrier and the breakthroughs in therapeutic shuttle transporters that target the brain in the Blood-Brain-Barrier Conference, an event organised by IRB Barcelona and supported by the BBVA Foundation.
One of the latest results is a shuttle based on bee venom developed at IRB Barcelona.
The medical newspaper Diario Médico has echoed on the research performed by Natàlia Carulla's group that has recently been published in Scientific Reports, a journal that belongs to the Nature group. The study offers data that challenge current views about the number and the shape of the first aggregates formed by amyloid beta protein, a molecule related to Alzheimer's...
Natàlia Carulla’s research group provides information that questions the widely accepted premise regarding the number of molecules and the shape of the first aggregates formed by amyloid beta protein
Amyloid beta protein aggregation, the process by which molecules of this protein adhere to each other is strongly associated with the development of Alzheimer’s disease
Carulla’s work ultimately seeks to identify molecules that interfere with the initial stages of aggregation as a strategy to combat the disease.